Praxis Precision Medicines, Inc. Common Stock PRAX
Analyst Ratings
- Consensus
- Buy — 16 Buy · 1 Hold · 1 Sell (18 analysts)
- Avg. Price Target
- $543.44 (+48.2% upside)
Key Stats
- Today's Range
- $355.11 – $368.40
- 50-Day Range
- $238.77 – $388.00
- 52-Week Range
- $37.19 – $388.00
- Volume
- 262K shs
- Average Volume
- 397K shs
- Market Cap
- $10.77 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 8.03
- Price / Sales
- —
Short Interest
- Short Interest
- 1.95%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- —
- Net Income
- $-339,126,000
- Net Margin
- —
- Return on Equity
- -25.29%
- Debt-to-Equity
- —
About Praxis Precision Medicines, Inc. Common Stock
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Related Stocks
Compare head-to-head: PRAX vs LLY·PRAX vs JNJ·PRAX vs ABBV·PRAX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.